Abstract
The monoclonal antibody bevacizumab, which neutralizes vascular endothelial growth factor, significantly affects the migration, survival, and proliferation of cells - all of which are critical for the growth and spread of tumors. The current study`s objective was to create polyurethane structures that are more soluble in water so they may be employed as this active agent`s transmembrane carrier. A polymer drug delivery system was created using an aliphatic isocyanate and a combination of ether and ester polyols, resulting in a suitable release profile and membrane penetrability. The solubility, pH, and refractivity index measurements, the size distribution and surface charge, the encapsulation efficacy and release profile, the proliferation of cells, and skin irritation tests on mice were used to describe the two samples. Our findings reveal that nearly neutral acido-basic polymer structures were achieved, ranging in size from 187 to 423 nm. Zeta potential values suggest a minor alteration in the propensity to form clusters in the sample with increased solubility, and UV-Vis analyses demonstrate an approximately 63±2% encapsulation efficacy. In terms of the samples` biosafety profile, the tests conducted on mouse skin and cell cultures did not result in significant adverse effects at the concentrations that were examined. The results of this preclinical investigation indicate that adding polar groups to polyurethane macromolecular chains improves aqueous solubility without changing the polymer carrier`s other properties.
Keywords: cells culture; drug delivery; mice skin; UV-Vis; Zetasizer